This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, today announced it has entered the next phase of its manufacturing collaboration with GE Healthcare ("GE"). The new phase involves GE final assembly, packaging and shipping of C-Scan capsules initially to support the Company's US pilot trial expected in 1H2018. Check-Cap will supply GE with supporting calibration and final assembly methodology and equipment.
Bill Densel, CEO of Check-cap commented, "We are very pleased to advance our collaboration with GE, moving forward with the initiation of this next phase that prepares us for our C-Scan capsule needs, beginning with our planned US pilot trial in 1H2018. Planning and other activities are also underway for our European post approval study, which is also expected in 1H2018."
